NCT05546853已完成1 期
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
University Hospital, Grenoble9 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2023年3月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 9
- 主要终点
- Percentage Proportion of patients experiencing adverse events
研究概览
简要总结
The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.
详细描述
The study is a multicentric, prospective, single arm phase 1b trial. This study will enroll 43 to 52 patients and consists of 2 parts: Safety Lead-in Phase and Expansion Phase. Initially, 3 to 12 patients will be enrolled into a Safety Lead-in Phase based on a 3 + 3 design, with the possibility of dose de-escalation, to confirm the recommended dose of NP137.The Expansion Phase will start after completion of Safety Lead-in Phase at the confirmed dose and will include 40 patients. Patients will be assigned to the experimental arm (NP137 + mFOLFIRINOX).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age from 18 to 79 years
- •Able to understand and sign informed consent
- •Histologically or cytologically proven diagnosis of pancreatic ductal adenocarcinoma
- •Locally advanced pancreatic cancer considered unresectable according to NCCN Guidelines® Version 2.2021
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors RECIST 1.1 criteria
- •Male, or non-pregnant and non-lactating female
- •Women patients of childbearing potential* must have a negative serum/urine pregnancy test at screening and baseline, and be willing to use a highly effective** contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for > 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential
- •Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration
- •No prior systemic therapy, radiation therapy, or resection for pancreatic cancer
- •Life expectancy ≥ 12 weeks
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Adequate liver function:
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN),
- •Bilirubin ≤ 1.5 x ULN or in subjects with biliary stenting ≤ 2.0 x ULN
- •Alkaline phosphatase < 2.5 x ULN
- •Subjects with biliary stenting do not need to wait for their alkaline phosphatase to become < 2.5 x ULN if their total bilirubin, AST and ALT have improved to within required study levels with criteria 12a and 12b
- •Adequate bone marrow function: platelets >100,000 cells/mm3, hemoglobin > 9.0 g/dl and absolute neutrophil count (ANC) >1,500 cells/mm3
- •Adequate renal function: creatinine < 1.5 x ULN, creatinine clearance ≥ 30 mL/min/m2
- •Adequate nutritional state with Albumin ≥ 2.5 g/dL
- •Less than grade 2 pre-existing peripheral neuropathy (per CTCAE)
- •Patients covered by Health Insurance System
排除标准
- •Patients with resectable pancreatic cancer
- •Evidence of the presence of metastases.
- •Patients who have received prior systemic therapy, radiation therapy, or resection for pancreatic cancer or prior therapy with NP137
- •Patients with known Dihydropyrimidine dehydrogenase (DPD) deficiency, or homozygosity for UGT1A1*28 polymorphism (UGT1A1 genotype analysis is not required to be eligible)
- •Previous (within the past 3 years) or concurrent malignancy diagnosis except non-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)
- •History of severe (grade ≥ 3) allergic reactions to one of the components of chemotherapy, or NP137
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, may decrease subject's compliance to study's procedures or may render the patient at high risk from treatment complications in the opinion of the treating investigator
- •Subjects with known poorly controlled comorbid conditions, including; congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), uncontrolled diabetes mellitus (DM) or neurologic disorders (not acutely related to pancreatic cancer) or limited function
- •Major surgery within 4 weeks prior to signing informed consent form. Biliary stents are permitted
- •History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
- •History of allergy or hypersensitivity to any of the chemotherapy agents belonging to mFOLFIRINOX regimen
- •Subjects with a history of chronic HCV, HBV or HIV infection
- •Subjects who have been administered a live vaccine within four weeks prior to the first administration of therapy
- •Subjects who cannot stop chronic medications that inhibit or induce CYP2C8 or CYP3A4
- •Persons referred to in Articles L1121-5 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure)
- •Patients who have active infection requiring systemic therapy (other than HCV, HBV, HIV).
- •Patients who participate or plan to participate in another interventional clinical trial or who is in exclusion period for another study.
研究组 & 干预措施
Experimental
Experimental
NP137+ mFOLFIRINOX
干预措施: 5 FU (Drug)
Experimental
Experimental
NP137+ mFOLFIRINOX
干预措施: NP137 (Drug)
Experimental
Experimental
NP137+ mFOLFIRINOX
干预措施: Irinotecan (Drug)
Experimental
Experimental
NP137+ mFOLFIRINOX
干预措施: Calcium levofolinate (Drug)
Experimental
Experimental
NP137+ mFOLFIRINOX
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
Percentage Proportion of patients experiencing adverse events
时间窗: At 6 months
Percentage Proportion of patients experiencing adverse events (AEs) of any grade and grade 3/4 AEs as defined by the National Cancer Institute - Common Terminology Criteria for Adverse Events (CTCAE v 5.0) at 6 months.
次要结局
- Best overall objective response rate (ORR)(At 3,6,9 and 12 months)
- Overall survival (OS)(at 6, 12 and 36 months)
- Progression-Free Survival (PFS)(at 6, 12 and 36 months)
- Median Duration of response(at 6 and 36 months)
- Quality of life (QoL)(at 6 and 36 months)
- time to deterioration(at 6 and 36 months)
- PK-PD evaluation(at 36 months)
- CA19.9 response(at 6 and 12 months)
- proportion of patients reaching surgery(at 6 and 36 months)
- Mechanisms of EMT(At month 0)
研究者
研究点 (9)
Loading locations...
相似试验
尚未招募
1 期
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic CancerPancreatic CancerNCT06203821Aram Hezel25
进行中（未招募）
1 期
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCHepatocellular CarcinomaNCT05546879University Hospital, Grenoble43
终止
1 期
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]Acute Myeloid Leukemia RefractoryNCT06150040Centre Leon Berard1
进行中（未招募）
1 期
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or PembrolizumabEndometrial CarcinomaCervix CarcinomaNCT04652076NETRIS Pharma240
终止
1 期
FOLFIRINOX + NIS793 in Pancreatic CancerPancreas CancerMetastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT05417386Colin D. Weekes, M.D., PhD4